Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: Implication of MTHFR RS1801133 and ATIC RS4673993 polymorphisms

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Lima, Aurea ^a,b,c   Monteiro, Joaquim ^a   Bernardes, Miguel ^d,e   Sousa, Hugo ^b,d   Azevedo, Rita ^b,d   Seabra, Vitor ^a   Medeiros, Rui ^b,c,f  

^a INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d University of Porto   (Portugal)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

^f LPCC Portuguese League Against Cancer (NRNorte)   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE ADENOSINE RIBONUCLEOTIDE TRANSFORMYLASE; ANTINUCLEAR ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RIBONUCLEOTIDE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; DEAMINASE; INOSINE MONOPHOSPHATE SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; MULTIENZYME COMPLEX; TRANSFERASE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONFOUNDING VARIABLE; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG USE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT RISK; PHARMACOGENETICS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMOKING; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; CONTROLLED STUDY; GENETICS; MIDDLE AGED; PORTUGAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIENZYME COMPLEXES; NUCLEOTIDE DEAMINASES; POLYMORPHISM, GENETIC; PORTUGAL; RISK FACTORS;

EID: 84902174947     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/368681     Document Type: Article

References (60)

1. Imboden J. B., Hellmann D. B., Stone J. H., Imboden J. B., Hellmann D. B., Stone J. H., Rheumatoid arthritis: the disease-diagnosis and clinical features. Current Rheumatology Diagnosis & Treatment 2006 2nd McGraw Hill Professional 508
2. van der Heijden J. W., Dijkmans B. A. C., Scheper R. J., Jansen G., Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nature Clinical Practice Rheumatology 2007 3 1 26 34 2-s2.0-33847004704 10.1038/ncprheum0380
3. Anderson J. J., Wells G., Verhoeven A. C., Felson D. T., Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis & Rheumatism 2000 43 1 22 29 (Pubitemid 30368209)
4. Fonseca J. E., Canhão H., Teixeira da Costa J. C., Pereira da Silva J. A., Viana Queiroz M., Global functional status in rheumatoid arthritis: disease duration and patient age. Clinical Rheumatology 2002 21 1 32 34 2-s2.0-0036206337 10.1007/s100670200008 (Pubitemid 34257438)
5. Rönnelid J., Wick M. C., Lampa J., Lindblad S., Nordmark B., Klareskog L., Van Vollenhoven R. F., Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Annals of the Rheumatic Diseases 2005 64 12 1744 1749 2-s2.0-27844610761 10.1136/ard.2004.033571 (Pubitemid 41667149)
6. Papadopoulos N. G., Alamanos Y., Voulgari P. V., Epagelis E. K., Tsifetaki N., Drosos A. A., Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clinical and Experimental Rheumatology 2005 23 6 861 866 2-s2.0-29944440423 (Pubitemid 43040515)
7. Morel J., Combe B., How to predict prognosis in early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology 2005 19 1 137 146 2-s2.0-10844287991 10.1016/j.berh.2004.08.008 (Pubitemid 40003945)
8. Hider S. L., Buckley C., Silman A. J., Symmons D. P. M., Bruce I. N., Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Journal of Rheumatology 2005 32 1 11 16 2-s2.0-11844294053 (Pubitemid 40092583)
9. van der Helm-van Mil A. H. M., Verpoort K. N., Breedveld F. C., Toes R. E. M., Huizinga T. W. J., Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Research & Therapy 2005 7 5 R949 R958 2-s2.0-27844575688
10. Urano W., Taniguchi A., Yamanaka H., Tanaka E., Nakajima H., Matsuda Y., Akama H., Kitamura Y., Kamatani N., Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002 12 3 183 190 2-s2.0-0036263469 10.1097/00008571-200204000-00002 (Pubitemid 34596782)
11. Aggarwal P., Naik S., Mishra K. P., Aggarwal A., Misra R., Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian Journal of Medical Research 2006 124 521 526 2-s2.0-33846482501 (Pubitemid 46157711)
12. Ranganathan P., McLeod H. L., Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis & Rheumatism 2006 54 5 1366 1377 2-s2.0-33646487007 10.1002/art.21762
13. Wessels J. A. M., de Vries-Bouwstra J. K., Heijmans B. T., Slagboom P. E., Goekoop-Ruiterman Y. P. M., Allaart C. F., Kerstens P. J. S. M., Van Zeben D., Breedveld F. C., Bijkmans B. A. C., Huizinga T. W. J., Guchelaar H.-J., Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis & Rheumatism 2006 54 4 1087 1095 2-s2.0-33646354882 10.1002/art.21726 (Pubitemid 43672921)
14. Iannaccone C. K., Lee Y. C., Cui J., Frits M. L., Glass R. J., Plenge R. M., Solomon D. H., Weinblatt M. E., Shadick N. A., Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology 2011 50 1 40 46 2-s2.0-79951703895 10.1093/rheumatology/ keq263
15. Owen S. A., Hider S. L., Martin P., Bruce I. N., Barton A., Thomson W., Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics Journal 2012 13 3 227 234 2-s2.0-84858715085 10.1038/tpj.2012.7
16. Dervieux T., Furst D., Lein D. O., Capps R., Smith K., Walsh M., Kremer J., Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis & Rheumatism 2004 50 9 2766 2774 2-s2.0-4444376725 10.1002/art.20460 (Pubitemid 39209513)
17. Halilova K. I., Brown E. E., Morgan S. L., Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? International Journal of Rheumatology 2012 2012 7 10.1155/2012/978396 978396
18. Romao V. C., Canhao H., Fonseca J. E., Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Medicine 2013 11, article 17
19. Vesell E. S., Advances in pharmacogenetics and pharmacogenomics. Journal of Clinical Pharmacology 2000 40 9 930 938 2-s2.0-0033668881
20. Tian H., Cronstein B. N., Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2007 65 3 168 173 2-s2.0-38449094689 (Pubitemid 351412127)
21. Chan E. S. L., Cronstein B. N., Molecular action of methotrexate in inflammatory diseases. Arthritis Research 2002 4 4 266 273 2-s2.0-0035985787 10.1186/ar419 (Pubitemid 34716307)
22. van Ede A. E., Laan R. F., Blom H. J., De Abreu R. A., Van de Putte L. B. A., Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Seminars in Arthritis and Rheumatism 1998 27 5 277 292 2-s2.0-0031950185 10.1016/S0049-0172(98)80049-8 (Pubitemid 28176234)
23. Palmer J. L., Abeles R. H., The mechanism of action of S-adenosylhomocysteinase. Journal of Biological Chemistry 1979 254 4 1217 1226 2-s2.0-0018800321
24. Dervieux T., Greenstein N., Kremer J., Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis & Rheumatism 2006 54 10 3095 3103 2-s2.0-33750352061 10.1002/art.22129 (Pubitemid 44622078)
25. Kurzawski M., Pawlik A., Safranow K., Herczynska M., Drozdzik M., 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 2007 8 11 1551 1559 2-s2.0-37349048292 10.2217/14622416.8.11.1551 (Pubitemid 350286399)
26. Lee Y. C., Cui J., Costenbader K. H., Shadick N. A., Weinblatt M. E., Karlson E. W., Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology 2009 48 6 613 617 2-s2.0-65849298666 10.1093/rheumatology/ken513
27. Hinks A., Moncrieffe H., Martin P., Ursu S., Lal S., Kassoumeri L., Weiler T., Glass D. N., Thompson S. D., Wedderburn L. R., Thomson W., Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 2011 70 8 1395 1400 2-s2.0-79959809380 10.1136/ard.2010.146191
28. Owen S. A., Lunt M., Bowes J., Hider S. L., Bruce I. N., Thomson W., Barton A., MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics Journal 2012 13 2 137 147 2-s2.0-80052845710 10.1038/tpj.2011.42
29. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J. H., Den Heijer M., Kluijtmans L. A. J., Van den Heuvel L. P., Rozen R., A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995 10 1 111 113 2-s2.0-0029049553
30. Aletaha D., Neogi T., Silman A. J., 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases 2010 69 9 1580 1588
31. Ortiz Z., Shea B., Suarez Almazor M., Moher D., Wells G., Tugwell P., Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2000 2 CD000951 2-s2.0-0033649435
32. Ortiz Z., Shea B., Suarez-Almazor M. E., Moher D., Wells G. A., Tugwell P., The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. Journal of Rheumatology 1998 25 1 36 43 2-s2.0-0031985832 (Pubitemid 28060115)
33. Lima A., Bernardes M., Sousa H., SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics 2013
34. Prevoo M. L. L., van 'T Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B. A., van Riel P. L. C. M., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism 1995 38 1 44 48 2-s2.0-0028815803 10.1002/art.1780380107
35. Sadananda Adiga M. N., Chandy S., Ramachandra N., Appaji L., Aruna Kumari B. S., Ramaswamy G., Savithri H. S., Krishnamoorthy L., Methylenetetrahydrofolate reductase gene polymorphisms and risk of acute lymphoblastic leukemia in children. Indian Journal of Cancer 2010 47 1 40 45 2-s2.0-75749092993 10.4103/0019-509X.58858
36. Gibofsky A., Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. The American Journal of Managed Care 2012 18 13, supplement S295 S302
37. Rindfleisch J. A., Muller D., Diagnosis and management of rheumatoid arthritis. American Family Physician 2005 72 6 1037 1047 2-s2.0-26944465819 (Pubitemid 43093259)
38. Bohanec Grabar P., Logar D., Lestan B., Dolžan V., Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. European Journal of Clinical Pharmacology 2008 64 11 1057 1068 2-s2.0-55349093579 10.1007/s00228-008-0521-7
39. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Rodriguez L., Miranda-Filloy J. A., Fernandez-Gutierrez B., Llorca J., Martin J., Gonzalez-Gay M. A., A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Research and Therapy 2010 12 2, article R71 2-s2.0-77951238604 10.1186/ar2989
40. Fenech M., The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutation Research. Fundamental and Molecular Mechanisms of Mutagenesis 2001 475 1-2 57 67 2-s2.0-0035906327 10.1016/S0027-5107(01)00079-3 (Pubitemid 32280803)
41. Świerkot J., Szechiński J., Methotrexate in rheumatoid arthritis. Pharmacological Reports 2006 58 4 473 492 2-s2.0-33748653376 (Pubitemid 44383273)
42. Dervieux T., Furst D., Lein D. O., Capps R., Smith K., Caldwell J., Kremer J., Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Annals of the Rheumatic Diseases 2005 64 8 1180 1185 2-s2.0-23444443994 10.1136/ard.2004. 033399 (Pubitemid 41113353)
43. Dervieux T., Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability. Rheumatology 2009 48 6 597 598 2-s2.0-65849260738 10.1093/rheumatology/kep060
44. Vardavas C. I., Linardakis M. K., Hatzis C. M., Malliaraki N., Saris W. H., Kafatos A. G., Smoking status in relation to serum folate and dietary vitamin intake. Tobacco Induced Diseases 2008 4, article 8
45. Gabriel H. E., Crott J. W., Ghandour H., Chronic cigarette smoking is associated with diminished folate status, altered folate form distribution, and increased genetic damage in the buccal mucosa of healthy adults. American Journal of Clinical Nutrition 2006 83 4 835 841 (Pubitemid 44713148)
46. Mannino D. M., Mulinare J., Ford E. S., Schwartz J., Tobacco smoke exposure and decreased serum and red blood cell folate levels: data from the third National Health and Nutrition Examination Survey. Nicotine and Tobacco Research 2003 5 3 357 362 2-s2.0-0038481232 10.1080/14622200307209 (Pubitemid 36764031)
47. Nouri-Shirazi M., Guinet E., Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003 109 3 365 373 2-s2.0-0038127069 10.1046/j.1365-2567.2003.01655.x (Pubitemid 36783262)
48. Kalra R., Singh S. P., Pena-Philippides J. C., Langley R. J., Razani-Boroujerdi S., Sopori M. L., Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model. Clinical and Diagnostic Laboratory Immunology 2004 11 3 563 568 2-s2.0-2442639095 10.1128/CDLI.11.3.563-568.2004 (Pubitemid 38661424)
49. Saevarsdottir S., Wedrén S., Seddighzadeh M., Bengtsson C., Wesley A., Lindblad S., Askling J., Alfredsson L., Klareskog L., Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish Rheumatology Register cohorts. Arthritis & Rheumatism 2011 63 1 26 36 2-s2.0-78650794601 10.1002/art.27758
50. Vesperini V., Lukas C., Fautrel B., le Loet X., Rincheval N., Combe B., Tobacco exposure reduces radiographic progression in early rheumatoid arthritis. Results from the ESPOIR cohort. Arthritis Care & Research 2013
51. Finckh A., Dehler S., Costenbader K. H., Gabay C., Cigarette smoking and radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 8 1066 1071 2-s2.0-34547225631 10.1136/ard.2006.065060 (Pubitemid 47122321)
52. Visser K., Goekoop-Ruiterman Y. P. M., De Vries-Bouwstra J. K., Ronday H. K., Seys P. E. H., Kerstens P. J. S. M., Huizinga T. W. J., Dijkmans B. A. C., Allaart C. F., A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the Best study. Annals of the Rheumatic Diseases 2010 69 7 1333 1337 2-s2.0-77954962834 10.1136/ard.2009. 121160
53. Hetland M. L., Stengaard-Pedersen K., Junker P., Østergaard M., Ejbjerg B. J., Jacobsen S., Lottenburger T., Hansen I., Tarp U., Andersen L. S., Svendsen A., Pedersen J. K., Lauridsen U. B., Ellingsen T., Lindegaard H., Pødenphant J., Vestergaard A., Jurik A. G., Hørslev-Petersen K., Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Annals of the Rheumatic Diseases 2010 69 10 1789 1795 2-s2.0-77957261808 10.1136/ard.2009.125534
54. Balsa A., del Amo J., Blanco F., Caliz R., Silva L., Sanmarti R., Martínez F. G., Tejedor D., Artieda M., Pascual-Salcedo D., Oreiro N., Collado M. D., Andreu J. L., Graell E., Simón L., Martínez A., Mulero J., Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms. Rheumatology 2009 49 3 458 466 2-s2.0-77950525477 10.1093/rheumatology/kep380 kep380
55. Agrawal S., Misra R., Aggarwal A., Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clinical Rheumatology 2007 26 2 201 204 2-s2.0-33845899372 10.1007/s10067-006-0275-5 (Pubitemid 46020244)
56. Saevarsdottir S., Wallin H., Seddighzadeh M., Ernestam S., Geborek P., Petersson I. F., Bratt J., Van Vollenhoven R. F., Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Annals of the Rheumatic Diseases 2011 70 3 469 475 2-s2.0-79951512652 10.1136/ard.2010.139212
57. Wessels J. A. M., van der Kooij S. M., Le Cessie S., Kievit W., Barerra P., Allaart C. F., Huizinga T. W. J., Guchelaar H.-J., A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis & Rheumatism 2007 56 6 1765 1775 2-s2.0-34447508090 10.1002/art.22640 (Pubitemid 47110376)
58. Riazzoli J., Nilsson J. A., Teleman A., Petersson I. F., Rantapää-Dahlqvist S., Jacobsson L. T. H., van Vollenhoven R. F., Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level. Rheumatology 2010 49 11 2098 2103 2-s2.0-78649341605 10.1093/rheumatology/ keq197
59. Hoekstra M., van Ede A. E., Haagsma C. J., Van De Laar M. A. F. J., Huizinga T. W. J., Kruijsen M. W. M., Laan R. F. J. M., Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2003 62 5 423 426 2-s2.0-0037404893 10.1136/ard.62.5.423 (Pubitemid 36469732)
60. Tuková J., Chládek J., Němcová D., Chládková J., Doležalová P., Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 2009 27 6 1047 1053 2-s2.0-76649119089